



OPEN ACCESS

EDITED AND REVIEWED BY
Frederic Becq,
University of Poitiers, France

*CORRESPONDENCE
Jochen G. Mainz,
✉ j.mainz@klinikum-brandenburg.de

†These authors have contributed equally
to this work

‡These authors share last authorship

RECEIVED 17 April 2023
ACCEPTED 21 April 2023
PUBLISHED 03 May 2023

CITATION

Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D and Schwarz C (2023), Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. *Front. Pharmacol.* 14:1207356. doi: 10.3389/fphar.2023.1207356

COPYRIGHT

© 2023 Mainz, Zagoya, Polte, Naehrlich, Sasse, Eickmeier, Smaczny, Barucha, Bechinger, Duckstein, Kurzidim, Eschenhagen, Caley, Peckham and Schwarz. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Jochen G. Mainz^{1,2*†}, Carlos Zagoya^{1†}, Louise Polte¹, Lutz Naehrlich^{3,4}, Lenny Sasse³, Olaf Eickmeier⁵, Christina Smaczny⁵, Anton Barucha¹, Lilith Bechinger¹, Franziska Duckstein¹, Ludwik Kurzidim^{1,6}, Patience Eschenhagen⁶, Laura Caley⁷, Daniel Peckham^{7,8‡} and Carsten Schwarz^{6‡}

¹Cystic Fibrosis Center, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany, ²Faculty of Health Sciences Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany, ³Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany, ⁴Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Giessen, Germany, ⁵Christiane Herzog CF-Zentrum Frankfurt am Main, Universitätsklinikum Frankfurt am Main CF-Zentrum, Frankfurt am Main, Germany, ⁶CF-Zentrum Westbrandenburg, Campus Potsdam, Klinikum Westbrandenburg, Potsdam, Germany, ⁷Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom, ⁸Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

KEYWORDS

gastrointestinal, patient reported outcome measure, CFTR modulators, elexacaftor, symptom score


A Corrigendum on

[Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score](#)

by Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D and Schwarz C (2022). *Front. Pharmacol.* 13:877118. doi: 10.3389/fphar.2022.877118

In the published article, there was an error in [Figure 1](#) as published. The figure itself including the proportion of changes is correct. However, the numbers representing percent changes in reduction of symptoms do not correspond to those mentioned in the text but rather to a preliminary calculation from a smaller cohort of patients. Noteworthy, the improvement in abdominal symptoms assessed with the CFAbd-Score during ETI is in fact markedly higher in the now corrected version. The corrected [Figure 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.